Model Accurately Predicts Risk of Oral Cancer Progression

This article originally appeared here.
Model Accurately Predicts Risk of Oral Cancer Progression
Model Accurately Predicts Risk of Oral Cancer Progression

(HealthDay News) -- A model that incorporates loss of heterozygosity data can accurately predict which patients with low-grade oral cancer are likely to progress to higher grades, according to a study published online Aug. 21 in Cancer Prevention Research.

Lewei Zhang, Ph.D., from the University of British Columbia in Vancouver, Canada, and colleagues analyzed samples from 296 patients with mild-to-moderate (low-grade) oral dysplasia to classify the risk of progression based on a previously proposed loss of heterozygosity model.

The researchers found that five-year progression rates were 3.1 percent for patients classified as low risk, 16.3 percent for those classified as intermediate risk, and 63.1 percent for those classified as high risk. The risk of progression was 11.6-fold greater in patients at intermediate risk and 52.1-fold greater in patients at high risk, compared with those at low risk. The model was validated in an independent group of patients.

"In summary, this study provides the first validated molecular models for use in differentiating low-grade oral dysplasia at low risk for progression from those with greater risk, via the largest longitudinal study of low-grade oral premalignant lesions from a population-based patient group," Zhang and colleagues conclude.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Editorial (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs